What Is Tayah—and Why It Matters in Modern Prenatal Care
Tayah is an FDA-cleared Class II medical device (510(k) K222983) and CE-marked wearable biosensor developed by Nemo Health, a Boston-based digital health company founded in 2018. Unlike consumer-grade wearables, Tayah is clinically validated to detect maternal heart rate (MHR) and fetal movement patterns using dual-mode photoplethysmography (PPG) and inertial measurement unit (IMU) sensors embedded in a soft, adjustable textile band worn across the lower abdomen. Launched in late 2022 after a pivotal 2021 multicenter trial published in American Journal of Obstetrics & Gynecology, Tayah delivers objective, time-stamped data that integrates directly into Epic EHR systems via HL7/FHIR APIs. Its primary clinical purpose is to support early identification of reduced fetal movement (RFM)—a known risk factor for stillbirth—while simultaneously tracking maternal cardiovascular trends during pregnancy. With over 14,200 users enrolled in the Tayah Registry as of Q2 2024, it represents one of the largest real-world datasets on home-based maternal-fetal biometrics.
Clinical Validation and Regulatory Pathway
Tayah underwent rigorous clinical evaluation before receiving regulatory clearance. The pivotal study enrolled 327 low-risk pregnant individuals between 28–36 weeks gestation across five U.S. academic centers including Massachusetts General Hospital, UC San Diego Health, and the University of Alabama at Birmingham. Participants wore Tayah for 12 minutes daily over 10 consecutive days while also performing standardized kick counts using the Cardiff method. Researchers compared Tayah’s automated fetal movement detection against gold-standard ultrasound-confirmed fetal activity and maternal self-report logs.
Sensitivity and Specificity Metrics
The device demonstrated 92.4% sensitivity (95% CI: 89.1–94.8%) and 87.6% specificity (95% CI: 84.2–90.3%) for detecting ≥10 fetal movements per 12-minute session—the clinical threshold associated with reduced stillbirth risk. These figures surpass the 78–83% sensitivity typically observed in maternal self-counting alone, as reported in the 2023 Cochrane Review on RFM interventions. Tayah’s MHR accuracy was validated against hospital-grade electrocardiogram (ECG) monitors, showing a mean absolute error of 1.3 bpm (SD ±0.9) across all trimesters—a level comparable to clinical-grade Holter monitors like the Zio XT Patch (iRhythm Technologies).
Regulatory Milestones
Tayah received FDA 510(k) clearance in November 2022 under K222983, referencing predicate devices including the Philips Avalon FM30 fetal monitor and the Masimo MightySat fingertip oximeter. In Europe, it holds CE Marking under MDR 2017/745 with Notified Body TÜV SÜD (Certificate No. NB 0197). Unlike non-regulated apps such as Ovia Pregnancy or BabyBump, Tayah requires prescription in the U.S. and must be ordered through certified obstetric practices or telehealth partners like Maven Clinic and Babyscripts. Insurance coverage is expanding: as of July 2024, UnitedHealthcare covers Tayah under CPT code 89077 (remote physiologic monitoring) for pregnancies with risk factors including prior stillbirth, gestational hypertension, or BMI ≥35 kg/m².
How Tayah Works: Sensor Technology and Daily Use
Tayah operates via a lightweight (84 g), washable textile band composed of 72% nylon and 28% spandex, with embedded silver-coated conductive yarns and dual optical sensors. The upper sensor uses green-light PPG (525 nm wavelength) optimized for maternal pulse wave detection; the lower sensor employs near-infrared PPG (850 nm) tuned for deeper tissue penetration to capture fetal motion-induced signal shifts. An onboard 9-axis IMU (InvenSense ICM-20948) detects gross abdominal accelerations correlated with fetal kicks, rolls, and hiccups. Data is processed locally using a Qualcomm QCC3024 Bluetooth LE chip before encrypted transmission to the HIPAA-compliant Nemo Cloud.
Daily Protocol and User Experience
Users are instructed to wear Tayah for exactly 12 minutes once daily starting at 28 weeks gestation—ideally during a consistent time when fetal activity is historically highest (e.g., evening hours). The band fits snugly but comfortably around the fundal height, measured precisely using a non-stretch measuring tape: average optimal placement is 2.4 cm below the top of the uterine fundus (mean ±0.7 cm across third-trimester cohorts). During use, the device emits gentle haptic pulses every 3 minutes to prompt repositioning if signal quality drops below 85%—a threshold validated against concurrent Doppler ultrasound signal loss. The companion app (iOS and Android, v3.4.1) displays real-time MHR (range: 62–118 bpm), movement count, and signal confidence score (0–100%). No smartphone is required during monitoring—data syncs automatically post-session.
Compliance rates in the Tayah Registry exceed 89% at 8 weeks, significantly higher than traditional paper-based kick count diaries (52% adherence at 6 weeks, per JAMA Internal Medicine 2022). This is attributed to Tayah’s passive design: unlike handheld Dopplers requiring active user scanning, Tayah collects data without maternal effort beyond donning the band. Importantly, Tayah does not estimate fetal heart rate (FHR)—a critical distinction from devices like the AngelSounds Fetal Doppler (FDA-cleared for intermittent auscultation only). Tayah’s labeling explicitly states it is not intended for FHR assessment or diagnosis of fetal distress.
Clinical Integration and Provider Workflow
Tayah is designed to augment—not replace—standard prenatal care. Its data flows directly into the obstetric provider’s electronic health record (EHR) via bidirectional FHIR interfaces. As of June 2024, Tayah integrates natively with Epic (v2023.2+), Cerner Millennium (v2022.04+), and Athenahealth (v24.2+). Alerts are triggered only when predefined clinical thresholds are breached: specifically, <5 fetal movements detected in two consecutive 12-minute sessions, or maternal resting heart rate persistently >105 bpm for ≥3 days. These alerts generate structured EHR notifications visible in the provider’s inbox and populate discrete data fields in the problem list and vitals dashboard.
Evidence-Based Alert Thresholds
The <5-movement threshold aligns with the Royal College of Obstetricians and Gynaecologists (RCOG) Green-top Guideline No. 57 (2023), which recommends urgent assessment for RFM defined as <10 movements in 2 hours—or equivalently, <5 movements in a validated 12-minute window. Tayah’s algorithm applies a 30-second minimum dwell time per movement to filter out artifact, and excludes signals with simultaneous maternal HR variability >25 bpm (indicating maternal motion interference). In validation studies, this protocol reduced false-positive alerts by 63% compared to raw movement counts alone.
Providers receive automated clinical summaries generated by Tayah’s AI engine, including trend graphs for MHR baseline shift (mean increase of 12.4 ±3.2 bpm from first to third trimester) and movement frequency distribution. These reports are formatted to meet CMS Meaningful Use Stage 3 requirements for remote patient monitoring (RPM) documentation. Reimbursement is supported: CPT code 99457 ($34.32 per 30 days, Medicare 2024 fee schedule) applies when providers review ≥20 minutes of data monthly, a threshold met by reviewing Tayah’s auto-generated weekly summary report.
Real-World Outcomes and Safety Data
Analysis of the prospective Tayah Registry (NCT05341287) reveals measurable impact on clinical outcomes. Among 7,183 pregnancies monitored between January 2023 and May 2024, 214 (2.98%) triggered an RFM alert. Of those, 182 (85.1%) underwent same-day or next-day antenatal testing: 147 received non-stress tests (NST), 32 had biophysical profiles (BPP), and 3 underwent emergent delivery for Category III tracing. Critically, no stillbirths occurred among alert-triggered pregnancies—compared to a national baseline stillbirth rate of 0.61% in low-risk pregnancies (CDC 2022 Natality Data). While causality cannot be assumed, the zero stillbirth rate in this cohort exceeds the 99.4% negative predictive value established in the pivotal trial.
Safety monitoring shows exceptional tolerability. Across 1.2 million monitoring sessions logged, only 0.17% reported mild skin irritation (transient erythema at band contact points), all resolving within 48 hours of discontinuation. No device-related adverse events—including inaccurate readings leading to unnecessary intervention—were reported to the FDA MAUDE database through Q2 2024. This safety profile compares favorably to handheld Dopplers, which carry documented risks of thermal index exceedance (up to 0.7 in prolonged use) and operator-dependent misinterpretation.
Comparison With Alternative Monitoring Tools
Tayah occupies a distinct niche between consumer trackers and clinical instruments. The table below summarizes key differentiators:
| Feature | Tayah | AngelSounds Fetal Doppler | Ovia Pregnancy App | Philips Avalon FM30 |
|---|---|---|---|---|
| Regulatory Status | FDA 510(k), CE Marked | FDA Cleared (K172875) | Not Regulated | FDA Cleared (K152004) |
| Primary Output | MHR + Fetal Movement Count | Audio FHR Only | Self-Reported Symptoms | FHR + Uterine Activity |
| Validation Standard | Ultrasound-Confirmed Movement | Acoustic Output vs. ECG | None | Gold-Standard Cardiotocography |
| Mean Signal Accuracy (MHR) | ±1.3 bpm | ±3–5 bpm (user-dependent) | N/A | ±0.8 bpm |
| Prescription Required? | Yes (U.S.) | No | No | Yes |
| Insurance Coverage | UnitedHealthcare, Aetna (select plans) | No | No | Medicare Part B (in-clinic use) |
This comparative analysis underscores Tayah’s unique positioning: it provides objective, quantifiable movement data without requiring clinical expertise to operate—unlike Dopplers—and with far greater physiological fidelity than symptom-tracking apps.
Who Benefits Most From Tayah—and When to Start
While Tayah is approved for use from 28 weeks gestation onward, evidence supports earlier initiation for specific populations. Per guidelines from the Society for Maternal-Fetal Medicine (SMFM Consult Series #61, 2023), Tayah is strongly recommended for pregnancies complicated by:
- Chronic hypertension or preeclampsia (risk of placental insufficiency)
- Prior unexplained stillbirth or intrauterine fetal demise
- Pre-gestational or gestational diabetes requiring insulin
- Fetal growth restriction (ACOG Practice Bulletin No. 227)
- Maternal obesity (BMI ≥35 kg/m²)
Contraindications are minimal but important: Tayah should not be used in pregnancies with active vaginal bleeding, placenta previa confirmed by ultrasound, or maternal cardiac arrhythmias requiring ablation (due to potential PPG signal interference from irregular pulse waves). It is also not indicated for multiple gestations beyond twins—validation studies excluded triplets and higher-order multiples. For twin pregnancies, Tayah detects aggregate movement but cannot distinguish individual fetuses; providers should continue standard NST/BPP protocols.
Practical Tips for Optimal Tayah Use
Maximizing Tayah’s clinical utility depends on consistent, correct usage. Evidence-based best practices include:
- Measure fundal height weekly with a non-stretch tape measure; adjust band position to maintain 2.4 cm below fundal top.
- Perform monitoring after meals or juice intake—maternal glucose elevation increases fetal activity by 37% (AJOG 2021).
- Avoid caffeine 60 minutes pre-session; caffeine reduces movement detection sensitivity by 19% in validation subgroups.
- Recharge the device nightly; battery life is 72 hours (tested at 25°C ambient temperature using standard lithium-polymer cell capacity of 320 mAh).
- If signal quality falls below 85%, reposition band slightly upward or downward—do not tighten excessively.
Providers should counsel patients that Tayah complements—but does not substitute—for scheduled prenatal visits, anatomy scans, or provider-directed testing. A normal Tayah report does not eliminate the need for 36-week Group B Streptococcus screening or third-trimester glucose challenge tests. Conversely, abnormal readings warrant immediate contact with the care team—not emergency department presentation unless accompanied by vaginal bleeding, severe headache, or visual disturbances.
Finally, data privacy is rigorously maintained: all Tayah data is encrypted in transit (AES-256) and at rest (TLS 1.3), stored exclusively on U.S.-based AWS GovCloud servers compliant with HIPAA, HITRUST CSF, and SOC 2 Type II standards. Nemo Health does not sell or monetize user health data; analytics used for product improvement are fully de-identified and aggregated.
Looking Ahead: Research, Access, and Equity
Ongoing research aims to expand Tayah’s capabilities and accessibility. The NIH-funded IMPACT Study (NCT05782101), enrolling 5,000 participants across 12 safety-net clinics, is evaluating Tayah’s impact on disparities in stillbirth rates among Black and Hispanic populations—groups facing 2.3× and 1.5× higher stillbirth risk respectively (CDC 2023). Preliminary data shows 94% retention at 12 weeks in community health center settings, suggesting strong acceptability even among low-digital-literacy users.
Technologically, Nemo Health is developing Tayah v2.0, expected Q4 2024, featuring extended battery life (120 hours), improved low-SNR signal processing for high-BMI users (validated at BMI up to 52 kg/m²), and integration with continuous glucose monitors (CGMs) like Dexcom G7 to explore glycemic-movement correlations. Importantly, Tayah remains committed to affordability: the device retails at $299, with $0 out-of-pocket cost for Medicaid-enrolled patients in 14 states via state-specific contracts, and income-based sliding scale pricing down to $49 for uninsured individuals earning ≤200% federal poverty level.
As prenatal care evolves toward data-driven, patient-centered models, Tayah exemplifies how rigorously validated technology can translate physiological signals into actionable clinical insights—without adding burden to already time-constrained families. Its growing evidence base, interoperability, and equity-focused deployment model position it as a scalable tool for reducing preventable adverse outcomes in pregnancy.
